OBLON
SPIVAK
MCCLELLAND
MAIER
&
NEUSTADT
RC.

FOR IFW

#### **FACSIMILE**

MESSAGE

TO **Examiner Saidha** ATTORNEYS AT LAW NAME PTO 571-273-0940 **FOURTH FLOOR** COMPANY/FIRM FAX# 1755 JEFFERSON DAVIS HIGHWAY ARLINGTON, VIRGINIA 22202 NUMBER OF PAGES INCLUDING COVER: CONFIRM FAX: YES NO (703) 413-3000 FROM Thomas M. Cunningham 220738US (703) 413-2220 FACSIMILE NAME OUR REFERENCE OBLONPATOOBLON.COM 703-412-6563 10/088,092 DIRECT PHONE # YOUR REFERENCE PATENT. TRADEMARK AND COPYRIGHT LAW AND RELATED FEDERAL AND ITC LITIGATION

PLEASE CALL US AT (703) 413-3000 IF THE MESSAGE YOU RECEIVE IS INCOMPLETE OR NOT LEGIBLE

WWW.OBLON,COM

#### Dear Examiner Saidha:

Thank you for the signed and initialed copy of the IDS filed 3/21/02. We are still missing a signed copy of the IDS filed 3/10/2003 which lists (6) documents. Please find attached a copy of this IDS for your convenience.

Would you sign and return fax this 1449 to us?

Please call me if you have any questions.

With best regards,

Thomas M. Cunningham

Unless otherwise indicated or obvious from the nature of the transmittal, the information contained in this facsimile message is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error or are not sure whether it is privileged, please immediately notify us by telephone and return the original message to us at the above address via the U.S. Postal Service at our Expense. Thank You.

<b>/</b>	• •
<i>J</i>	$\smile$
1 000 0 100 1 PT 54 000 000 000 000 000 000 000 000 000	Dept.: NFO/smp FF
OSMM&N File No. 220738US0PCT	Due Date: 03/10/03
Serial No. 10/088,092	
In the matter of the Application of: Jun ISH	
For: A GENE ENCODING NOVEL HUMA PHOSPHOLIPASE A2  The following has been received in the U.S. F  Check for  Assignment: 2 pages/PTO 1595	
Information Disclosure Statement	
Cited References (6)	Dep. Acct. Order Form
Statement of Relevancy	<b>■</b> PTO-1449
European Scarch Report	□ Cited Pending
☐ IDS/Related/List of Related Cases	Applications

Postd PCT/PTO 10 MAR 2003

™O. 564

Docket No.

220738US0PCT

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Jun ISHIZAKI, et al.

SERIAL NO: 10/088,092

GAU:

FILED:

March 21, 2002

EXAMINER:

FOR:

A GENE ENCODING NOVEL HUMAN SECRETORY TYPE PHOSPHOLIPASE A2

# INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

SIR:

Applicant(s) wish to disclose the following information.

#### REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

#### RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s)
- ☐ A check is attached in the amount required under 37 CFR §1.17(p).

### CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of
- No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to

# DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Tel. (703) 413-3000 Fax. (703) 413-2220 (O\$MMN 03/02)

Norman F. Oblon

Registration No. 24,618

Surinder Sachar

Registration No. 34,423

				·		SHE	ET 1	OF
Form PTO 1449	OFFI		SERIAL N	10.				
(Modified) PATENT AND TRADEMARK OFFICE		220738US0PCT		10/088,0	092			
			APPLICANT					
LIST OF	REF	ERENCES CITED BY APPLIC	CANT	Jun ISHIZAKI, et al.				
				FILING DATE		GROUP	160	
				March 21, 2002	•		165	$\alpha_{-}$
				U.S. PATENT DOCUMENTS		L		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS		IG DATE ROPRIATE
	AA	<del></del>						
	AB							
	AÇ							
_	AD							
	AE							
	AF							
	AG							
	AH							
	Al							
	AJ				<del>                                     </del>		<del></del>	
	AK				+	<del></del>		
	AL				-			
	AM				<del>  -  </del>			
	AN				<del> </del>		<del></del>	
		•	FOR	EIGN PATENT DOCUMENTS				
		DOCUMENT NUMBER	ATE	COUNTRY		TR	PANSLATI	ON
	AO					YES	·	_NO
	AP	<del></del>						
	AQ							
<u></u>	<u></u> _1	OTHER RESERVE						
100		Jun ISHIZAKI et al . "Clooks	INCES (In	cluding Author, Title, Date, Pertinent	Pages, etc	.)		
18	AR	08/27/99	OI IEMIO I	acterization of novel mouse and human RY, vol. 274, no. 35, pages 24973-245	179			
1	AS	Y. YOKOTA et al.: "Suppres independent mechanisms"	sion of mu	rine endotoxic shock by sPLA2 inhibito	r, indoxam,	through grou	IP IIA SPL	A2-
+ +		BIOCHIMICA ET BIOPHYSIO 05/18/99		vol. 1438, no. 2, pages 213-222				
1	~'	inhibitors, SPI* BIOCHIMICA ET BIOPHYSIC 11/23/99	:A ACTA,	design of a new class of anti-inflamm vol. 1441, no. 2-3, pages 223-228	atory drugs:	secretory pl	rospholipa	ise A2
11,	λU .	E.A. DENNIS: "The growing	phospholip CAL SCIE	pase A2 superfamily of signal transduct NCES, vol. 22, no. 1, pages 1-2	ion enzyme:	37		
,	¥V :	G. LAMBEAU et al.: "Recept TRENDS IN PHARMACOLOG	ors for a gr	owing family of secreted phospholipas ENCES, vol. 20, no. 4, pages 162-170	e A2"	· · · · · · · · · · · · · · · · · · ·		
1/2/		Noriko SUZUKI et al.: "Struct	ures anav	matic properties, and supposite of				
48 A	w   ;			pholipase A2s* RY, vol. 275, no. 8, pages 5785-5793	Addition	al Referenc	es sheet(s	s) attached
miner		T. Swidh			Date Consid		131/	<u></u>
aminer: Initia formance and	l if ref	erence is considered, whethe considered. Include copy of the	or not cit is form wit	ation is in conformance with MPEP 608 th next communication to applicant.	; Draw line t	hrough citat	on if not in	n
-cepy	Df	Ethis DS was			1/	1		



# SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application Number EP 00 96 1047

1	DOCUMENTS CONSID	ERED TO BE RELEVANT			
Category	Citation of document with it of relevant pass	ndication, where appropriate, sages	Relevant to daim	CLASSIFICATION OF THE APPLICATION (Int.CI.7)	
<b>X</b>	JUN ISHIZAKI ET AL: characterization of secretory phospholi JOURNAL OF BIOLOGIC vol. 274, no. 35, 27 August 1999 (199 24973-24979, XP0021 * the whole document	novel mouse and human pase A2s" AL CHEMISTRY, 9-08-27), pages 30207	1-16	C12N9/20 C12N15/55 C12P21/02 C12P21/08 C07K16/40	
X,D	endotoxic shock by indoxam, through gr sPLA2-independent m BIOCHIMICA ET BIOPH vol. 1438, no. 2,	oup IIA echanisms"	17,18		
P,X	MIHELICH E D ET AL: design of a new cla drugs: secretory ph inhibitors, SPI" BIOCHIMICA ET BIOPH vol. 1441, no. 2-3, 23 November 1999 (1 223-228, XP00427727 * figure 1 *	ass of anti-inflammatory nospholipase A2 NYSICA ACTA, 1999-11-23), pages	17,18	TECHNICAL FIELDS SEARCHED (Int.CI.7)	
A	DENNIS E A: "The g superfamily of sign enzymes" TIBS TRENDS IN BIOG ELSEVIER PUBLICATIO vol. 22, no. 1, 199 XP004016851 ISSN: 0968-0004 * the whole document	HEMICAL SCIENCES, ON, CAMBRIDGE, EN, O7, pages 1-2,	1-18		
	The supplementary search reposet of claims valid and available	nt has been based on the last at the start of the search.			
	Place of search	Date of completion of the search		Examiner	
	MUNICH	27 January 2003	Wei	k1, M	
X: part Y: part docu A: tech O: non	ATEGORY OF CITED DOCUMENTS icularly relevant if taken alone icularly relevant if combined with another of the same category nological background—written disclosure mediate document	T : theory or princip E : earlier patent do after the filling da	cument, but publite in the application for other reasons	ished on, or	

1



# SUPPLEMENTARY EUROPEAN SEARCH REPORT

Application Number EP 00 96 1047

		DERED TO BE RELEVANT	<del></del>	
Category	Citation of document with of relevant pa	n indication, where appropriate, assages	Relevant to daim	CLASSIFICATION OF T APPLICATION (Int.CI.7
	TRENDS IN PHARMACO ELSEVIER TRENDS JO		g 1-18	
	phospholipase A2s. JOURNAL OF BIOLOGI vol. 275, no. 8.	es, and expression of use secretory	1-16	
	5785-5793, XP00222 ISSN: 0021-9258 * the whole docume	8755		
			·	TECHNICAL FIELDS SEARCHED (Int.CI.7
	-R			
				•
	ne supplementary search repo et of claims valid and available	rt has been based on the last at the start of the search.		
	face of search	Date of completion of the search	<u> </u>	Examiner
	UNICH	27 January 2003	Weik1	, M
: particul : particul docume : technok	EGORY OF CITED DOCUMENTS arly relevant if taken alone arly relevant if combined with anot ent of the same category ogical background itten disclosure	E : earlier patent doc	ument, but publishe e the application	ntion d on, or

1